CONTACT:Investors:Kim Sutton GolodetzO: 212-838-3777KGolodetz@lhai.comBruce VossO: 310-691-7100 BVoss@lhai.comMedia:Lisa GuitermanO: 301-217-9353C: email@example.com
BRISBANE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present how innovative pricing approaches, such as the company's Responsible Pricing Model, can fortify existing incentives to bring therapies to the U.S. for neglected diseases during the Priority Review Voucher (PRV) Summit in Arlington, Va., November 2-3, 2016. Dr. Durrant will also participate in a separate panel to discuss PRVs as a model to support the research and development of important medicines. "The current PRV system is enlightened policy driving both immediate help, and future advancements, for neglected disease patients," said Dr. Durrant. "We look forward to engaging in the conversation around serving the public health through these effective FDA incentives and responsible drug pricing." Details of the presentation and panel follow: Title: Tackling Neglected Diseases through Responsible Pricing Date: Wednesday, November 2, 2016 Time: 3:00 - 3:45 p.m. EDT Presenter: Dr. Cameron Durrant, KaloBios Pharmaceuticals Title: Panel: Priority Review Vouchers: A New Paradigm for Funding Research Date: Wednesday, November 2, 2016 Time: 4:15 - 5:15 p.m. EDT Participants: Xi Chen, PhD, Adena Partners Management; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Charles Keller, MD, Children's Cancer Therapy Development Institute; Curt H. LaBelle, MD, Global Health Investment Fund For more information on the conference, please visit http://exlevents.com/priorityreviewvoucher/. About KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.